PDI, Inc. Subsidiary Interpace Diagnostics Enters Molecular Diagnostics Market with Thyroid and Pancreatic Cancer Test Portfolio Acquisition

Transaction Marks First Step Toward Creation of a Molecular Diagnostics Subsidiary to Aid in Patient Diagnosis and Management

Aug 13, 2014, 16:03 ET from PDI, Inc.